January 4, 2018
Sonoran Biosciences is a presenting company at Biotech Showcase 2018
Sonoran Biosciences, Inc., a preclinical-stage pharmaceutical company developing a novel antibacterial gel for the treatment and prevention of serious biofilm infections, today announced that its chief executive officer, Derek Overstreet, PhD, will deliver a corporate presentation at the 10th Annual Biotech Showcase, held January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco. The presentation will take place on January 9th at 10:45am PST at the Hilton San Francisco Union Square in Franciscan D.
About Biotech Showcase
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
About Sonoran Biosciences, Inc.
Sonoran Biosciences is a preclinical-stage pharmaceutical company developing a novel antibacterial gel for the treatment and prevention of serious biofilm infections, especially those that occur after surgery. The company’s lead product SBG002 is an injectable sustained-release gel containing tobramycin and vancomycin designed for direct application in surgical sites. SBG002 has the potential to become a first-in-class product for treatment and prevention of a wide variety of serious infections, and is being developed toward a lead indication in one-stage treatment of periprosthetic joint infection (PJI), the most common and costly reason for failed arthroplasty.